The construction industry is on the lookout for cost-effective structural members that are also environmentally friendly. Built-up cold-formed steel (CFS) sections with minimal thickness can be used to make beams at a lower cost. Plate buckling in CFS beams with thin webs can be avoided by using thick webs, adding stiffeners, or strengthening the web with diagonal rebars. When CFS beams are designed to carry heavy loads, their depth logically increases, resulting in an increase in building floor height. The experimental and numerical investigation of CFS composite beams reinforced with diagonal web rebars is presented in this paper. A total of twelve built-up CFS beams were used for testing, with the first six designed without web encasement and the remaining six designed with web encasement. The first six were constructed with diagonal rebars in the shear and flexure zones, while the other two with diagonal rebars in the shear zone, and the last two without diagonal rebars. The next set of six beams was constructed in the same manner, but with a concrete encasement of the web, and all the beams were then tested. Fly ash, a pozzolanic waste byproduct of thermal power plants, was used as a 40% replacement for cement in making the test specimens. CFS beam failure characteristics, load–deflection behavior, ductility, load–strain relationship, moment–curvature relationship, and lateral stiffness were all investigated. The results of the experimental tests and the nonlinear finite element analysis performed in ANSYS software were found to be in good agreement. It was discovered that CFS beams with fly ash concrete encased webs have twice the moment resisting capacity of plain CFS beams, resulting in a reduction in building floor height. The results also confirmed that the composite CFS beams have high ductility, making them a reliable choice for earthquake-resistant structures.
The interplay between the environmental exposome and the cancer genome remains a critical "blind spot" in precision oncology. While somatic mutational signatures genomic fossils imprinted by exposures such as ultraviolet radiation, tobacco smoke, and industrial pollutants are well characterized for their etiological significance, their functional impact on therapeutic efficacy remains largely unexplored. We hypothesized that these environmental "genomic scars" induce distinct pharmacogenomic vulnerabilities (collateral sensitivity) and resistance mechanisms (collateral resistance) that vary by geographical exposure patterns. Here, we present the first global "Geo-Pharmacogenomic" atlas, integrating 41 COSMIC mutational signatures with drug response profiles from 1,001 cancer cell lines across four large-scale pharmacogenomic screens (GDSC1, GDSC2, CTRP, CCLE). By harmonizing disparate drug sensitivity metrics and applying rigorous statistical controls for tissue lineage, we identified and validated 608 significant signature-drug interactions (P < 0.01). We demonstrate that UV-associated signature SBS7a is a broad-spectrum driver of therapeutic resistance, conferring intrinsic insensitivity to BRAF inhibitors (PLX-4720, P < 10-4) and Notch inhibitors globally. Conversely, we uncover a novel synthetic lethal vulnerability wherein pollution-driven oxidative stress (SBS18) sensitizes tumors to p38 MAPK inhibition (VX-702, r = -0.45, P < 10-9). Synthesizing these findings with satellite-derived atmospheric data (World Bank/NASA AOD), we constructed a Kriging-interpolated risk surface spanning 122 nations. This analysis predicts distinct "Resistance Landscapes with high-intensity drug resistance predicted in pollution-dense megacities (e.g., Beijing, New Delhi) challenging the paradigm of uniform drug efficacy. Our results establish environmental history as a functional biomarker, necessitating a paradigm shift towards geographically stratified precision medicine.
The interplay between the environmental exposome and the cancer genome remains a critical gap in precision oncology. While somatic mutational signatures—genomic fossils imprinted by exposures such as ultraviolet radiation; tobacco smoke; and industrial pollutants—are well characterised for their etiological significance; their functional impact on therapeutic efficacy remains largely unexplored. We hypothesised that these environmental genomic scars induce distinct pharmacogenomic vulnerabilities and resistance mechanisms that vary by geographical exposure patterns. This study employs two complementary analytical frameworks. First, a linear regression-based pharmacogenomic screen across four datasets (GDSC1, GDSC2, CTRP, CCLE; 1001 cell lines, 31 cancer types) identified 608 statistically significant (p < 0.01) mutational signature–drug interactions, revealing that UV-associated signature SBS7a is associated with broad-spectrum therapeutic resistance, including to BRAF inhibitors (PLX-4720, p < 10−4), while pollution-driven oxidative stress (SBS18) is associated with sensitivity to p38 MAPK inhibition (VX-702, r = −0.45, p < 10−9). Second, an XGBoost predictive model trained exclusively on 33,679 GDSC2 records using a 1265-feature matrix integrating 40 SBS signatures, drug chemistry descriptors, proteomic features, and two satellite-derived environmental variables (NASA PM2.5 and UV)—achieved R2 = 0.7973 on a 20% holdout set (grouped cross-validation R2 = 0.7296). SHAP analysis revealed that satellite-derived PM2.5 (Zone_PM25) ranked 7th of 1265 features, exceeding all 40 individual SBS mutational signatures. Synthesising these findings with satellite-derived atmospheric data, we constructed an exploratory spatially interpolated risk surface spanning 122 nations, generating the hypothesis that uniform drug efficacy assumptions may not apply globally. These findings suggest that a patient’s environmental exposure history may constitute a measurable pharmacogenomic variable. This exploratory framework warrants validation in independent datasets and with individual-level geographic data before clinical application.
Due of the extensive infrastructure development that India has been experiencing over the past thirty years, conventional stone aggregates are becoming scarcer and more expensive. However, there are plenty of wastes available, such as those from old concrete structures. Recycled concrete aggregate (RCA) wastes have already been the subject of numerous attempts to repurpose in a variety of building applications, including bituminous pavement layers. It's possible that not all bituminous binders that are frequently employed in Indian paving mixtures are compatible with RCA. The purpose of this experimental investigation is to examine how different types of binders affect the performance of densely graded bituminous mixtures in which RCA is used in place of the coarse portion of traditional stone aggregates. The primary goal of this project was to manufacture dense bituminous macadam (DBM) mixtures in accordance with pertinent Indian criteria. Traditional VG 30 and crumb rubber modified binder (CRMB), two forms of bituminous binders that are commonly used in India, were employed in this procedure. In accordance with the primary objective of this investigation, the blends were created and assessed about their technical attributes such as indirect tensile strength and moisture susceptibility traits like residual stability test and tensile strength ratio. The VG30 bitumen provides better and satisfactory results for combinations with an equal proportion of NA and RCA, taking into account all engineering properties evaluated.